1. How is patient care for multiple myeloma advancing?. Issue 6 (3rd June 2017) Authors: Genadieva Stavric, Sonja; Bonello, Francesca; Bringhen, Sara; Boccadoro, Mario; Larocca, Alessandra Journal: Expert review of hematology Issue: Volume 10:Issue 6(2017) Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. (October 2018) Authors: Bringhen, Sara; Offidani, Massimo; Palmieri, Salvatore; Pisani, Francesco; Rizzi, Rita; Spada, Stefano; Evangelista, Andrea; Di Renzo, Nicola; Musto, Pellegrino; Marcatti, Magda; Vallone, Roberto; Storti, Sergio; Bernardini, Annalisa; Centurioni, Riccardo; Aitini, Enrico; Palmas, Angelo; Annibali... Journal: Critical reviews in oncology/hematology Issue: Volume 130(2018) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Issue 9 (September 2019) Authors: Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik; Oriol, Albert; Simpson, David; George, Anupkumar; Goldschmidt, Hartmut; Larocca, Alessandra; Chanan-Khan, Asher; Sherbenou, Daniel; Avivi, Irit; Benyamini, Noam; Iida, Shinsuke; Matsumoto, Morio; Suzuki, Kenshi; Ribrag, Vincent; Usma... Journal: Lancet Issue: Volume 6:Issue 9(2019) Page Start: e459 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Issue 5 (18th December 2018) Authors: Gambella, Manuela; Omedé, Paola; Spada, Stefano; Muccio, Vittorio Emanuele; Gilestro, Milena; Saraci, Elona; Grammatico, Sara; Larocca, Alessandra; Conticello, Concetta; Bernardini, Annalisa; Gamberi, Barbara; Troia, Rossella; Liberati, Anna Marina; Offidani, Massimo; Rocci, Alberto; Palumbo, Ant... Journal: Cancer Issue: Volume 125:Issue 5(2019) Page Start: 750 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Issue 8 (30th April 2020) Authors: Milani, Paolo; Fazio, Francesca; Basset, Marco; Berno, Tamara; Larocca, Alessandra; Foli, Andrea; Riva, Marcello; Benigna, Francesca; Oliva, Stefania; Nuvolone, Mario; Rodigari, Lara; Petrucci, Maria Teresa; Merlini, Giampaolo; Palladini, Giovanni Journal: American journal of hematology Issue: Volume 95:Issue 8(2020:Aug.) Page Start: 900 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Novel investigational drugs active as single agents in multiple myeloma. (3rd June 2017) Authors: D'Agostino, Mattia; Salvini, Marco; Palumbo, Antonio; Larocca, Alessandra; Gay, Francesca Journal: Expert opinion on investigational drugs Issue: Volume 26:Number 6(2017) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials. (26th August 2021) Authors: Chen, Yan‐Ting; Valent, Erik T.; van Beers, Erik H.; Kuiper, Rowan; Oliva, Stefania; Haferlach, Torsten; Chng, Wee‐Joo; van Vliet, Martin H.; Sonneveld, Pieter; Larocca, Alessandra Journal: International journal of laboratory hematology Issue: Volume 44:Number 1(2022) Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Melflufen for relapsed and refractory multiple myeloma. (2nd October 2020) Authors: Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman; Hassoun, Hani; Rodríguez-Otero, Paula; Paner, Agne; Schjesvold, Fredrik H.; Gullbo, Joachim; Richardson, Paul G. Journal: Expert opinion on investigational drugs Issue: Volume 29:Number 10(2020) Page Start: 1069 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022) Authors: Dimopoulos, Meletios A; Richardson, Paul G; Bahlis, Nizar J; Grosicki, Sebastian; Cavo, Michele; Beksaç, Meral; Legieć, Wojciech; Liberati, Anna M; Goldschmidt, Hartmut; Belch, Andrew; Magen, Hila; Larocca, Alessandra; Laubach, Jacob P; Petrucci, Maria T; Reece, Donna; White, Darrell; Mateos, Mar... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. Issue 1 (2nd January 2017) Authors: Salvini, Marco; Bonello, Francesca; Boccadoro, Mario; Larocca, Alessandra Journal: Expert review of anticancer therapy Issue: Volume 17:Issue 1(2017) Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗